In situ gelatinolytic activity correlates with tumor progression and prognosis in patients with bladder cancer

Journal of Urology

Volumn 172, Issue 4 I, 2004, Pages 1480-1484

  Kawamura, Koji ^a   Kamiya, Naoto ^a   Suyama, Takahito ^a   Shimbo, Masaki ^a   Oosumi, Nobuyuki ^a   Suzuki, Hiroyoshi ^a   Ueda, Takeshi ^a   Tobe, Toyofusa ^a   Igarashi, Tatsuo ^a   Ito, Haruo ^a   Ishikura, Hiroshi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Bladder; Bladder neoplasms; Gelatinases; Matrix metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 4544358058     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000137749.99255.3e     Document Type: Article

References (20)

1. Shima, I., Sasaguri, Y., Kusukawa, J., Yamana, H., Fujita, H., Kakegawa, T. et al: Production of matrix metalloproteinases-2 and metalloproteinases-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study. Cancer, 70: 2747, 1992
2. Sier, C. F., Kubben, F. J., Ganesh, S., Heerding, M. M., Griffioen, G., Hanemaaijer, R. et al: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer, 74: 413, 1996
3. Liabakk, N. B., Talbot, I., Smith, R. A., Wilkinson, K. and Balkwill, F.: Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer, 56: 190, 1996
4. Talvensaari-Mattila, A., Paakko, P., Hoyhtya, M., Blanco-Sequeiros, G. and Turpeenniemi-Hujanen, T.: Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer, 83: 1153, 1998
5. Bramhall, S. R., Stamp, G. W., Dunn, J., Lemoine, N. R. and Neoptolemos, J. P.: Expression of collagenase (MMP2), stromelysin (MMP3), and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer, 73: 972, 1996
6. Stearns, M. and Stearns, M. E.: Evidence for increase activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol Res, 8: 69, 1996
7. Montironi, R., Lucarini, G., Castaldini, C., Galluzzi, C. M., Biagini, G. and Fabris, G.: Immunohistochemical evaluation of type IV collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia. Anticancer Res, 16: 2057, 1996
8. Kallakury, B. V., Karikehalli, S., Haholu, A., Sheehan, C. E., Azumi, N. and Ross, J. S.: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clinic Cancer Res, 7: 3113, 2001
9. Kugler, A., Hemmerlein, B., Thelen, P., Kallerhoff, M., Radzun, H.-J. and Ringert, R.-H.: Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol, 160: 1914, 1998
10. Davies, B., Waxman, J., Wasan, H., Abel, P., Williams, G., Krausz, T. et al: Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res, 53: 5365, 1993
11. Kanayama, H., Yokota, K., Kurokawa, Y., Murakami, Y., Nishitani, M. and Kagawa, S.: Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer, 82: 1359, 1998
12. Gerhards, S., Jung, K., Koenig, F., Daniltchenko, D., Hauptmann, S., Schnorr, D. et al: Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology, 57: 675, 2001
13. Furuya, M., Ishikura, H., Nemori, R., Shibata, M., Fujimoti, S. and Yoshiki, T.: Clarification of the active gelatinolytic sites in human ovarian neoplasms using in situ zymography. Hum Pathol, 32: 163, 2001
14. Zheng, K., Nagai, Y., Kishimoto, T., Yamazawa, K., Tate, S., Nemori, R. et al: A quantitative evaluation of active gelatinolytic sites in uterine endometrioid adenocarcinoma using film in situ zymography: association of stronger gelatinolysis with myometrial invasion. Jpn J Cancer Res, 93: 516, 2002
15. Ikeda, M., Maekawa, R., Tanaka, H., Matsumoto, M., Takeda, Y., Tamura, Y. et al: Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in situ zymography. Clinic Cancer Res, 6: 3290, 2000
16. Lengyel, E., Schmalfeldt, B., Konik, E., Spathe, K., Harting, K., Fenn, A. et al: Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol, 82: 291, 2001
17. Kamiya, N., Kishimoto, T., Suzuki, H., Sekita, N., Nagai, Y., Oosumi, N. et al: Increased in situ gelatinolytic activity in renal cell tumor tissues correlates with tumor size, grade and vessel invasion. Int J Cancer, 106: 480, 2003
18. Ozdemir, E., Kakehi, Y., Okuno, H. and Yoshida, O.: Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J Urol, 161: 1359, 1999
19. Hara, I., Miyake, H., Hara, S., Arakawa, S. and Kamidono, S.: Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. J Urol, 165: 1769, 2001
20. Papathoma, A. S., Petraki, C., Grigorakis, A., Papakonstantinou, H., Karavana, V., Stefanakis, S. et al: Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res, 20: 2009, 2000